Should be taken with food.
|
Severe hypertension, ventricular tachycardia, severe hyperthyroidism. Ophthalmic (10% solution): Close-angle glaucoma. Children and elderly. Cold preparations should not be used in children <2 years. Concomitant or within 14 days of MAOI use (oral).
|
Patient with CV disease (e.g. ischaemic heart disease, pre-existing bradycardia, partial heart block, severe coronary artery disease, heart failure, cardiogenic shock), diabetes mellitus, asthma, arteriosclerosis, aneurysm, hypertension, narrow-angle glaucoma. Renal impairment (IV). Children. Elderly. Pregnancy (especially those with history of pre-eclampsia) and lactation. Patient Counselling Eye drops may cause temporary blurring of vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure.
|
Significant: Reflex bradycardia, extravasation (IV); rebound miosis (ophthalmic);
Cardiac disorders: Arrhythmia, ischemia, extrasystoles, palpitation, tachycardia.
Eye disorders: Eye pain, irritation, stinging or burning sensation, blurred vision, photophobia, mydriasis, vitreous opacity (transient).
Gastrointestinal disorders: Nausea, vomiting.
Nervous system disorders: Headache, paresthesia,tremor, weakness.
Psychiatric disorders: Anxiety, agitation, insomnia, nervousness, excitability.
Renal and urinary disorders: Urinary retention (in males).
Respiratory, thoracic and mediastinal disorders:Skin and subcutaneous tissue disorders: Blanching of skin, pallor, piloerection.
Vascular disorders: Hypertension, hypertensive crisis.
Potentially Fatal: Cerebral haemorrhage, ventricular arrhythmia, myocardial infarction.
|
|
|
Concomitant use with adrenergic blocking agents (e.g. phentolamine), phenothiazine drugs (e.g. chlorpromazine) and amiodarone may cause antagonistic effects. May potentiate pressor effects of oxytocic drugs and CV depressant effects of inhalational anaesthetics (e.g. cyclopropane, halothane). May increase risk of arrythmias with cardiac glycosides and quinidine. May enhance the effects of anticholinergic drugs (e.g. TCAs).
|
|
|
R01AB01 - phenylephrine ; Belongs to the class of topical sympathomimetic combination preparations, excluding corticosteroids. Used as nasal decongestants.
C01CA06 - phenylephrine ; Belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding glycosides. Used in the treatment of heart failure.
S01GA05 - phenylephrine ; Belongs to the class of sympathomimetics used as ophthalmologic decongestants.
S01FB01 - phenylephrine ; Belongs to the class of sympathomimetics used as mydriatics and cycloplegics.
R01BA03 - phenylephrine ; Belongs to the class of systemic sympathomimetic preparations used as nasal decongestants.
R01AA04 - phenylephrine ; Belongs to the class of topical sympathomimetic agents used as nasal decongestants.
|
Sign Out
